Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ATRA |
---|---|---|
09:32 ET | 9499 | 0.53395 |
09:34 ET | 1800 | 0.5217 |
09:36 ET | 900 | 0.529427 |
09:38 ET | 4229 | 0.5222 |
09:39 ET | 1305 | 0.5209 |
09:41 ET | 6300 | 0.5207 |
09:43 ET | 308 | 0.52 |
09:45 ET | 83198 | 0.52 |
09:48 ET | 6964 | 0.51895 |
09:50 ET | 2600 | 0.515 |
09:52 ET | 300 | 0.5187 |
09:54 ET | 13699 | 0.5122 |
09:56 ET | 7804 | 0.51195 |
09:57 ET | 4537 | 0.518799 |
09:59 ET | 2300 | 0.5241 |
10:01 ET | 2800 | 0.5128 |
10:03 ET | 2000 | 0.5165 |
10:06 ET | 4170 | 0.515 |
10:08 ET | 2100 | 0.5184 |
10:10 ET | 1876 | 0.5159 |
10:12 ET | 4526 | 0.5183 |
10:14 ET | 300 | 0.5184 |
10:15 ET | 3200 | 0.5159 |
10:17 ET | 8102 | 0.5128 |
10:19 ET | 4969 | 0.51505 |
10:21 ET | 400 | 0.5168 |
10:24 ET | 3300 | 0.5168 |
10:26 ET | 1300 | 0.5165 |
10:28 ET | 2988 | 0.5169 |
10:30 ET | 1700 | 0.5166 |
10:32 ET | 1000 | 0.5167 |
10:33 ET | 6900 | 0.52105 |
10:35 ET | 7829 | 0.5144 |
10:37 ET | 9856 | 0.5122 |
10:39 ET | 5173 | 0.5118 |
10:42 ET | 1000 | 0.5159 |
10:44 ET | 1100 | 0.5135 |
10:46 ET | 484 | 0.5159 |
10:48 ET | 50057 | 0.516 |
10:50 ET | 2250 | 0.51 |
10:51 ET | 4794 | 0.51 |
10:53 ET | 1211 | 0.5149 |
10:55 ET | 300 | 0.5142 |
10:57 ET | 3600 | 0.5128 |
11:00 ET | 5400 | 0.514299 |
11:02 ET | 700 | 0.5131 |
11:04 ET | 8900 | 0.5129 |
11:06 ET | 1300 | 0.5125 |
11:08 ET | 2300 | 0.5125 |
11:09 ET | 1009 | 0.5137 |
11:11 ET | 3361 | 0.5142 |
11:13 ET | 1700 | 0.5133 |
11:15 ET | 2955 | 0.51465 |
11:18 ET | 600 | 0.516 |
11:20 ET | 1512 | 0.5201 |
11:22 ET | 1853 | 0.5289 |
11:24 ET | 300 | 0.529 |
11:26 ET | 2750 | 0.52585 |
11:27 ET | 1600 | 0.5289 |
11:29 ET | 1429 | 0.5277 |
11:31 ET | 249 | 0.5277 |
11:33 ET | 500 | 0.5277 |
11:36 ET | 1217 | 0.5277 |
11:38 ET | 1655 | 0.5232 |
11:40 ET | 3303 | 0.5437 |
11:42 ET | 1139 | 0.5437 |
11:44 ET | 433 | 0.545 |
11:45 ET | 2584 | 0.545 |
11:47 ET | 400 | 0.545 |
11:49 ET | 100 | 0.545 |
11:51 ET | 732 | 0.545 |
11:54 ET | 11672 | 0.5499 |
11:56 ET | 46654 | 0.53695 |
11:58 ET | 800 | 0.5493 |
12:00 ET | 120 | 0.5494 |
12:02 ET | 11227 | 0.525237 |
12:03 ET | 600 | 0.537099 |
12:05 ET | 724 | 0.5372 |
12:07 ET | 3547 | 0.5261 |
12:09 ET | 2499 | 0.5262 |
12:12 ET | 6090 | 0.5368 |
12:14 ET | 11425 | 0.529 |
12:16 ET | 814 | 0.52495 |
12:18 ET | 500 | 0.5246 |
12:20 ET | 6094 | 0.52 |
12:21 ET | 10528 | 0.5276 |
12:23 ET | 1500 | 0.5359 |
12:25 ET | 217 | 0.52595 |
12:30 ET | 1989 | 0.5315 |
12:32 ET | 1412 | 0.526975 |
12:36 ET | 1873 | 0.53 |
12:38 ET | 799 | 0.525 |
12:39 ET | 300 | 0.5299 |
12:41 ET | 5600 | 0.5299 |
12:43 ET | 300 | 0.5299 |
12:45 ET | 1527 | 0.5287 |
12:48 ET | 42193 | 0.518616 |
12:50 ET | 1700 | 0.5143 |
12:52 ET | 580 | 0.5143 |
12:56 ET | 178 | 0.5159 |
12:57 ET | 11067 | 0.52 |
12:59 ET | 4267 | 0.5117 |
01:01 ET | 2181 | 0.519 |
01:03 ET | 2876 | 0.52 |
01:06 ET | 1928 | 0.51505 |
01:08 ET | 147 | 0.52 |
01:12 ET | 1932 | 0.51495 |
01:14 ET | 100 | 0.51495 |
01:15 ET | 3480 | 0.51745 |
01:17 ET | 700 | 0.51745 |
01:19 ET | 1100 | 0.5175 |
01:21 ET | 1600 | 0.51745 |
01:24 ET | 2165 | 0.5198 |
01:26 ET | 1687 | 0.5128 |
01:28 ET | 2200 | 0.5128 |
01:30 ET | 4842 | 0.5128 |
01:32 ET | 500 | 0.5198 |
01:33 ET | 1000 | 0.5125 |
01:35 ET | 2189 | 0.5111 |
01:39 ET | 2100 | 0.5107 |
01:42 ET | 2100 | 0.511 |
01:44 ET | 100 | 0.5107 |
01:46 ET | 700 | 0.5107 |
01:48 ET | 992 | 0.5107 |
01:50 ET | 2317 | 0.5156 |
01:53 ET | 500 | 0.5188 |
01:55 ET | 2100 | 0.5115 |
01:57 ET | 800 | 0.5115 |
02:00 ET | 400 | 0.5115 |
02:02 ET | 1100 | 0.5196 |
02:04 ET | 3297 | 0.5196 |
02:06 ET | 1640 | 0.5196 |
02:08 ET | 1859 | 0.5116 |
02:09 ET | 2474 | 0.5116 |
02:11 ET | 800 | 0.519 |
02:13 ET | 612 | 0.512 |
02:15 ET | 1000 | 0.51565 |
02:18 ET | 2100 | 0.51565 |
02:20 ET | 1861 | 0.519 |
02:22 ET | 300 | 0.51565 |
02:24 ET | 6901 | 0.5196 |
02:27 ET | 1600 | 0.52 |
02:29 ET | 250 | 0.5203 |
02:31 ET | 3512 | 0.527 |
02:33 ET | 400 | 0.5277 |
02:36 ET | 22239 | 0.5351 |
02:38 ET | 2221 | 0.5412 |
02:40 ET | 9845 | 0.5381 |
02:42 ET | 1316 | 0.5342 |
02:44 ET | 300 | 0.5351 |
02:45 ET | 8933 | 0.53 |
02:49 ET | 1000 | 0.53015 |
02:51 ET | 1100 | 0.5253 |
02:54 ET | 2400 | 0.53015 |
02:56 ET | 1100 | 0.535 |
02:58 ET | 700 | 0.5253 |
03:00 ET | 1500 | 0.5349 |
03:02 ET | 7152 | 0.542 |
03:03 ET | 8940 | 0.54 |
03:05 ET | 7025 | 0.5275 |
03:07 ET | 953 | 0.5275 |
03:09 ET | 19500 | 0.5235 |
03:12 ET | 5100 | 0.5236 |
03:14 ET | 77471 | 0.51 |
03:16 ET | 865 | 0.5092 |
03:18 ET | 500 | 0.5092 |
03:20 ET | 4994 | 0.5123 |
03:21 ET | 3288 | 0.5094 |
03:23 ET | 4800 | 0.5096 |
03:25 ET | 85669 | 0.49 |
03:27 ET | 15945 | 0.5056 |
03:30 ET | 7200 | 0.51 |
03:32 ET | 833 | 0.502 |
03:34 ET | 3970 | 0.5056 |
03:36 ET | 500 | 0.5012 |
03:38 ET | 300 | 0.5012 |
03:39 ET | 6801 | 0.505 |
03:41 ET | 2805 | 0.506 |
03:43 ET | 1050 | 0.5079 |
03:45 ET | 13009 | 0.5098 |
03:48 ET | 20231 | 0.506 |
03:50 ET | 6546 | 0.5055 |
03:52 ET | 5500 | 0.505 |
03:54 ET | 3950 | 0.5033 |
03:56 ET | 25881 | 0.505 |
03:57 ET | 20802 | 0.4973 |
03:59 ET | 90195 | 0.522 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Atara Biotherapeutics Inc | 63.7M | -0.2x | --- |
LAVA Therapeutics NV | 60.2M | -2.1x | --- |
DURECT Corp | 47.2M | -1.6x | --- |
Collplant Biotechnologies Ltd | 58.8M | -7.8x | --- |
Curis Inc | 52.1M | -0.9x | --- |
Kezar Life Sciences Inc | 49.8M | -0.5x | --- |
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $63.7M |
---|---|
Revenue (TTM) | $34.7M |
Shares Outstanding | 120.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.57 |
EPS | $-2.12 |
Book Value | $-0.93 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 1.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -669.19% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.